Eli Lilly (LLY): “I Still Like It” – Cramer Sees Opportunity on the Dip
We recently published a list of Jim Cramer’s Thoughts on These 7 Stocks. In this article, we are going to take a look at ...
Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
Poultry Medicine/Pharmaceuticals Market to Hit USD 6.68 Billion by 2029 with 5.9% CAGR | MarketsandMarkets
The poultry medicine/pharmaceuticals market valued at US$ 4.73 billion in 2023, is forecasted to grow at a robust CAGR of 5.9%, reaching US$ ...
cweb6d
Biogen Shares Rise on FDA Approval for Alzheimer’s Drug, But CWEB Analyst Insight Highlights Market Impact
Biogen Inc. (BIIB) saw its stock climb 1.7% on Monday afternoon, reaching a nearly two-week high following positive ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Allurion Catapults 132% On Its Plans To Outdo Eli Lilly, Novo Nordisk
Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...
Novo Nordisk Stock Soars on New Weight-Loss Drug Results
Novo Nordisk scored a much-needed win on Friday, with early-stage data on a new weight-loss drug that suggested it could work better than the obesity blockbusters already on the market. Novo American ...
Confidence Is Just As Dangerous When It's Too Low As When It's Too High
To attain goals, you need confidence. It takes self-assurance to pursue what matters most to you. But too much confidence has ...
The FDA is about to make weight-loss drugs a lot harder to get
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...